Cardiol Therapeutics Inc.
CRDL.TO
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -7.82% | -48.59% | -2.81% | -13.65% | 40.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.27% | -28.71% | -1.93% | -5.80% | 20.92% |
| Operating Income | 19.27% | 28.71% | 1.93% | 5.80% | -20.92% |
| Income Before Tax | 11.45% | 22.48% | -25.36% | 15.19% | -4.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.45% | 22.48% | -25.36% | 15.19% | -4.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.45% | 22.48% | -25.36% | 15.19% | -4.08% |
| EBIT | 19.27% | 28.71% | 1.93% | 5.80% | -20.92% |
| EBITDA | 19.11% | 27.75% | 1.26% | 5.20% | -20.73% |
| EPS Basic | 27.37% | 36.08% | -4.28% | 30.93% | 15.56% |
| Normalized Basic EPS | 27.31% | 36.05% | -4.34% | 30.96% | 15.61% |
| EPS Diluted | 27.37% | 36.08% | -4.28% | 30.93% | 15.56% |
| Normalized Diluted EPS | 27.31% | 36.05% | -4.34% | 30.96% | 15.61% |
| Average Basic Shares Outstanding | 21.81% | 21.31% | 20.22% | 22.82% | 23.39% |
| Average Diluted Shares Outstanding | 21.81% | 21.31% | 20.22% | 22.82% | 23.39% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |